Novo and Pfizer are among the investors set to exit the cancer therapy developer, which has set a $100m target for its initial public offering.

Bolt Biotherapeutics, a US-based oncology therapy developer backed by property developer Nan Fung and pharmaceutical firms Pfizer and Novo, has filed to raise up to $100m in its initial public offering. Founded in 2015 as a Stanford University spinout, Bolt is developing antibody drug conjugates to treat cancer and will channel part of the IPO…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.